B
IMUC

Bailard’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Bailard’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-56,250
Closed -$518K – 351
2016
Q2 		$518K Hold
56,250
– – 0.06% 196
2016
Q1 		$653K Buy
+56,250
New +$633K 0.09% 132
2015
Q4 		– Sell
-56,250
Closed -$945K – 402
2015
Q3 		$945K Buy
56,250
+23,921
+74% +$435K 0.15% 100
2015
Q2 		$610K Buy
+32,329
New +$622K 0.09% 129

Other funds holding IMUC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $177B AUM 39.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
GC
Guggenheim Capital Chicago, Illinois $15.9B AUM 53.4% 1-Year Est. Return
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM) Fort Worth, Texas $24.4B AUM 22.19% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bailard's IMUC Position: Q3 2016 in Review

Bailard sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q3 2016, closing a stake of 56,250 shares — an estimated $518K sold.

Bailard first reported a position in IMUC in Q2 2015 and held it in 4 quarters. The position peaked at $945K in Q3 2015. 31 funds tracked by Wall St. Rank hold IMUC as of Q3 2016.

  • Bailard reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q3 2016 after selling out during the quarter.
  • Bailard sold 56,250 ImmunoCellular Therapeutics, Ltd. shares in Q3 2016, an estimated $518K.
  • Bailard first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2015 and held it in 4 quarters.
  • Bailard's ImmunoCellular Therapeutics, Ltd. position peaked at $945K in Q3 2015.
  • 31 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q3 2016.

Based on Bailard's 13F filing for Q3 2016, filed 9 Nov 2016.